Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea
· Delayed Price · Currency is KRW 49,500
-2,000 (-3.88%)
Apr 29, 2026, 3:30 PM KST
Hanall Biopharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 155,185 | 138,944 | 134,910 | 109,995 | 101,594 | Upgrade
|
| Other Revenue | - | - | -0 | -0 | -0 | Upgrade
|
| Revenue | 155,185 | 138,944 | 134,910 | 109,995 | 101,594 | Upgrade
|
| Revenue Growth (YoY) | 11.69% | 2.99% | 22.65% | 8.27% | 14.66% | Upgrade
|
| Cost of Revenue | 74,410 | 65,738 | 59,870 | 48,120 | 41,364 | Upgrade
|
| Gross Profit | 80,775 | 73,206 | 75,040 | 61,876 | 60,231 | Upgrade
|
| Selling, General & Admin | 61,112 | 51,850 | 47,520 | 42,586 | 38,472 | Upgrade
|
| Research & Development | 19,315 | 19,993 | 23,945 | 16,498 | 10,462 | Upgrade
|
| Amortization of Goodwill & Intangibles | 12.88 | 15.93 | 80.19 | 135.64 | 181.24 | Upgrade
|
| Other Operating Expenses | 669.16 | 660.34 | 669.45 | 584.09 | 605.75 | Upgrade
|
| Operating Expenses | 82,386 | 72,975 | 73,296 | 60,370 | 50,132 | Upgrade
|
| Operating Income | -1,611 | 230.47 | 1,743 | 1,506 | 10,099 | Upgrade
|
| Interest Expense | -142.51 | -70.97 | -63.86 | -21.88 | -25.48 | Upgrade
|
| Interest & Investment Income | 263.11 | 490.32 | 1,227 | 1,427 | 719.84 | Upgrade
|
| Earnings From Equity Investments | -157.66 | -99.53 | -62.12 | -45.39 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -17.08 | -408.83 | 349.6 | -600.15 | -115.94 | Upgrade
|
| Other Non Operating Income (Expenses) | -91.09 | -203.55 | -1,067 | -228.48 | -745.87 | Upgrade
|
| EBT Excluding Unusual Items | -1,757 | -62.07 | 2,127 | 2,037 | 9,932 | Upgrade
|
| Gain (Loss) on Sale of Investments | -4,182 | 331.43 | 1,121 | -124.34 | -177.44 | Upgrade
|
| Gain (Loss) on Sale of Assets | 23.18 | -452.56 | -9.32 | 16.99 | -1,052 | Upgrade
|
| Asset Writedown | -264.6 | - | -36.72 | - | - | Upgrade
|
| Pretax Income | -6,180 | -183.2 | 3,203 | 1,929 | 8,702 | Upgrade
|
| Income Tax Expense | -620.72 | 1,622 | -306.08 | 1,678 | -194.05 | Upgrade
|
| Net Income | -5,559 | -1,805 | 3,509 | 251.47 | 8,896 | Upgrade
|
| Net Income to Common | -5,559 | -1,805 | 3,509 | 251.47 | 8,896 | Upgrade
|
| Net Income Growth | - | - | 1295.23% | -97.17% | -54.99% | Upgrade
|
| Shares Outstanding (Basic) | 51 | 51 | 51 | 51 | 51 | Upgrade
|
| Shares Outstanding (Diluted) | 51 | 51 | 51 | 51 | 51 | Upgrade
|
| Shares Change (YoY) | 0.13% | 0.04% | -0.24% | -0.76% | 0.05% | Upgrade
|
| EPS (Basic) | -109.48 | -35.59 | 69.21 | 4.95 | 173.74 | Upgrade
|
| EPS (Diluted) | -109.48 | -35.59 | 69.21 | 4.95 | 173.74 | Upgrade
|
| EPS Growth | - | - | 1298.63% | -97.15% | -55.01% | Upgrade
|
| Free Cash Flow | -3,288 | 7,718 | 27,231 | 22,434 | -3,766 | Upgrade
|
| Free Cash Flow Per Share | -64.76 | 152.20 | 537.18 | 441.48 | -73.55 | Upgrade
|
| Gross Margin | 52.05% | 52.69% | 55.62% | 56.25% | 59.29% | Upgrade
|
| Operating Margin | -1.04% | 0.17% | 1.29% | 1.37% | 9.94% | Upgrade
|
| Profit Margin | -3.58% | -1.30% | 2.60% | 0.23% | 8.76% | Upgrade
|
| Free Cash Flow Margin | -2.12% | 5.56% | 20.18% | 20.39% | -3.71% | Upgrade
|
| EBITDA | 1,950 | 3,351 | 4,990 | 4,558 | 12,824 | Upgrade
|
| EBITDA Margin | 1.26% | 2.41% | 3.70% | 4.14% | 12.62% | Upgrade
|
| D&A For EBITDA | 3,561 | 3,121 | 3,247 | 3,053 | 2,725 | Upgrade
|
| EBIT | -1,611 | 230.47 | 1,743 | 1,506 | 10,099 | Upgrade
|
| EBIT Margin | -1.04% | 0.17% | 1.29% | 1.37% | 9.94% | Upgrade
|
| Effective Tax Rate | - | - | - | 86.97% | - | Upgrade
|
| Advertising Expenses | 3,918 | 3,230 | 3,287 | 3,090 | 2,112 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.